To be or not to be a case of heparin resistance
Heparin resistance can be defined as high doses of unfractionated heparin (UFH), greater than 35,000 IU/day, required to raise the activated partial thromboplastin time (aPTT) and activated coagulation time (ACT) to within therapeutically desired ranges or the impossibility of doing so. The most com...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Greater Baltimore Medical Center
2018-05-01
|
| Series: | Journal of Community Hospital Internal Medicine Perspectives |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20009666.2018.1466599 |
| _version_ | 1797968094563401728 |
|---|---|
| author | Jibran Durrani Faizan Malik Naveed Ali Syed Imran Mustafa Jafri |
| author_facet | Jibran Durrani Faizan Malik Naveed Ali Syed Imran Mustafa Jafri |
| author_sort | Jibran Durrani |
| collection | DOAJ |
| description | Heparin resistance can be defined as high doses of unfractionated heparin (UFH), greater than 35,000 IU/day, required to raise the activated partial thromboplastin time (aPTT) and activated coagulation time (ACT) to within therapeutically desired ranges or the impossibility of doing so. The most common pathology responsible is the deficiency of anti-thrombin III (ATIII) deficiency. Other clinically relevant conditions that can present with heparin resistance are congenital deficiencies; use of high doses of heparin during extracorporeal circulation, use of asparaginase therapy and disseminated intravascular coagulation (DIC). Most of these conditions effect the ATIII levels. Patients are typically identified in an acute phase, when determination of the cause of resistance is challenging. We present a case where a patient presented with suspected heparin resistance in an acute phase of sickness, where timely intervention was able to prevent a potentially fatal situation. Abbreviations: Neuroendocrine tumors (NETs), World health Organization (WHO), Radiation therapy (RT) |
| first_indexed | 2024-04-11T02:40:25Z |
| format | Article |
| id | doaj.art-c4fbd962d77046b3ae7ffde024bc68e0 |
| institution | Directory Open Access Journal |
| issn | 2000-9666 |
| language | English |
| last_indexed | 2024-04-11T02:40:25Z |
| publishDate | 2018-05-01 |
| publisher | Greater Baltimore Medical Center |
| record_format | Article |
| series | Journal of Community Hospital Internal Medicine Perspectives |
| spelling | doaj.art-c4fbd962d77046b3ae7ffde024bc68e02023-01-02T19:08:03ZengGreater Baltimore Medical CenterJournal of Community Hospital Internal Medicine Perspectives2000-96662018-05-018314514810.1080/20009666.2018.14665991466599To be or not to be a case of heparin resistanceJibran Durrani0Faizan Malik1Naveed Ali2Syed Imran Mustafa Jafri3Temple University Hospital affiliateTemple University Hospital affiliateTemple University Hospital affiliateTemple University Hospital affiliateHeparin resistance can be defined as high doses of unfractionated heparin (UFH), greater than 35,000 IU/day, required to raise the activated partial thromboplastin time (aPTT) and activated coagulation time (ACT) to within therapeutically desired ranges or the impossibility of doing so. The most common pathology responsible is the deficiency of anti-thrombin III (ATIII) deficiency. Other clinically relevant conditions that can present with heparin resistance are congenital deficiencies; use of high doses of heparin during extracorporeal circulation, use of asparaginase therapy and disseminated intravascular coagulation (DIC). Most of these conditions effect the ATIII levels. Patients are typically identified in an acute phase, when determination of the cause of resistance is challenging. We present a case where a patient presented with suspected heparin resistance in an acute phase of sickness, where timely intervention was able to prevent a potentially fatal situation. Abbreviations: Neuroendocrine tumors (NETs), World health Organization (WHO), Radiation therapy (RT)http://dx.doi.org/10.1080/20009666.2018.1466599Activated partial thromboplastin time (aPTT)anti-thrombin III (ATIII)activated coagulation time (ACT)unfractionated heparin(UFH)low molecular weight heparin(LMWH)anti-factor 10a (AF 10a)pulmonary embolism (PE)disseminated intravascular coagulation (DIC) |
| spellingShingle | Jibran Durrani Faizan Malik Naveed Ali Syed Imran Mustafa Jafri To be or not to be a case of heparin resistance Journal of Community Hospital Internal Medicine Perspectives Activated partial thromboplastin time (aPTT) anti-thrombin III (ATIII) activated coagulation time (ACT) unfractionated heparin(UFH) low molecular weight heparin(LMWH) anti-factor 10a (AF 10a) pulmonary embolism (PE) disseminated intravascular coagulation (DIC) |
| title | To be or not to be a case of heparin resistance |
| title_full | To be or not to be a case of heparin resistance |
| title_fullStr | To be or not to be a case of heparin resistance |
| title_full_unstemmed | To be or not to be a case of heparin resistance |
| title_short | To be or not to be a case of heparin resistance |
| title_sort | to be or not to be a case of heparin resistance |
| topic | Activated partial thromboplastin time (aPTT) anti-thrombin III (ATIII) activated coagulation time (ACT) unfractionated heparin(UFH) low molecular weight heparin(LMWH) anti-factor 10a (AF 10a) pulmonary embolism (PE) disseminated intravascular coagulation (DIC) |
| url | http://dx.doi.org/10.1080/20009666.2018.1466599 |
| work_keys_str_mv | AT jibrandurrani tobeornottobeacaseofheparinresistance AT faizanmalik tobeornottobeacaseofheparinresistance AT naveedali tobeornottobeacaseofheparinresistance AT syedimranmustafajafri tobeornottobeacaseofheparinresistance |